- Home
- ONL vs CHRS Comparison
ONL vs CHRS Comparison
Compare ONL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- CHRS
- Stock Information
- Founded
- ONL 2021
- CHRS 2010
- Country
- ONL United States
- CHRS United States
- Employees
- ONL N/A
- CHRS N/A
- Industry
- ONL Real Estate Investment Trusts
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONL Real Estate
- CHRS Health Care
- Exchange
- ONL Nasdaq
- CHRS Nasdaq
- Market Cap
- ONL 119.7M
- CHRS 102.0M
- IPO Year
- ONL N/A
- CHRS 2014
- Fundamental
- Price
- ONL $2.55
- CHRS $0.91
- Analyst Decision
- ONL Hold
- CHRS Buy
- Analyst Count
- ONL 1
- CHRS 3
- Target Price
- ONL N/A
- CHRS $4.68
- AVG Volume (30 Days)
- ONL 370.5K
- CHRS 1.4M
- Earning Date
- ONL 08-06-2025
- CHRS 08-11-2025
- Dividend Yield
- ONL 3.13%
- CHRS N/A
- EPS Growth
- ONL N/A
- CHRS N/A
- EPS
- ONL N/A
- CHRS N/A
- Revenue
- ONL $154,796,000.00
- CHRS $272,251,000.00
- Revenue This Year
- ONL N/A
- CHRS N/A
- Revenue Next Year
- ONL N/A
- CHRS $142.61
- P/E Ratio
- ONL N/A
- CHRS N/A
- Revenue Growth
- ONL N/A
- CHRS 19.87
- 52 Week Low
- ONL $1.46
- CHRS $0.66
- 52 Week High
- ONL $4.39
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- ONL 54.98
- CHRS 50.88
- Support Level
- ONL $2.51
- CHRS $0.84
- Resistance Level
- ONL $2.72
- CHRS $1.15
- Average True Range (ATR)
- ONL 0.12
- CHRS 0.07
- MACD
- ONL -0.02
- CHRS -0.01
- Stochastic Oscillator
- ONL 37.14
- CHRS 22.14
About ONL Orion Office REIT Inc.
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.